中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

超声造影在肝细胞癌局部精准诊疗全流程管理中的应用

周燕 丁建民 经翔

引用本文:
Citation:

超声造影在肝细胞癌局部精准诊疗全流程管理中的应用

DOI: 10.12449/JCH260705
基金项目: 

国家自然科学基金 (82371986);

天津市医学重点学科建设资助 (TJYXZDXK-3-020c);

天津市医学重点专科(超声医学)项目 

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:周燕负责撰写文章;经翔负责拟定写作思路;丁建民、经翔负责指导撰写文章并最终定稿。
详细信息
    通信作者:

    经翔, dr.jingxiang@aliyun.com (ORCID: 0000-0001-9088-365X)

Application of contrast-enhanced ultrasound in the full-course management of precise locoregional diagnosis and treatment for hepatocellular carcinoma

Research funding: 

National Natural Science Foundation of China (82371986);

Tianjin Key Medical Discipline Construction Project (TJYXZDXK-3-020c);

Tianjin Key Medical Specialty (Ultrasonography) Project 

More Information
  • 摘要: 肝细胞癌(HCC)是我国疾病负担最为沉重的恶性肿瘤之一,多数患者确诊时已丧失根治性手术切除机会,局部介入治疗在HCC全程管理中的重要性日益提升。超声造影(CEUS)可实时、动态显示肿瘤微循环灌注特征,并具备床旁可用性、无电离辐射及可重复性等优势,其应用已从辅助诊断扩展至HCC精准局部诊疗的全流程管理。治疗前,CEUS可用于病灶的定性诊断、定位、活性范围评估及穿刺路径规划,提升常规超声显示不清病灶的辨识度;治疗中及治疗后,CEUS能够及时检测残余活性病灶、相关并发症及局部肿瘤进展,为补充消融、经导管动脉化疗栓塞或联合治疗策略的调整提供依据。CEUS肝脏影像报告和数据系统的治疗反应评估体系的建立,为局部治疗后疗效评价提供了标准化方案;同时,单模态及多模态融合影像技术的发展促进了CEUS在HCC精准局部诊疗中的规范化应用。随着对消融安全边界的进一步重视,局部消融疗效评价的核心已从“是否实现影像学完全消融”转向“无造影、不消融,无融合、不根治”的新治疗理念。本文围绕CEUS在HCC局部介入诊疗中的技术优势、临床应用价值、治疗反应评价、融合影像拓展及当前局限性展开述评,以期为HCC的个体化与精准化管理提供参考。

     

  • [1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [2] Chhikara B S, Parang K. Global Cancer Statistics 2022: the trends projection analysis[M]. Chem Biol Lett, 2023, 10( 1): 451.
    [3] Zeng H M, Zheng R S, Sun K X, et al. Cancer survival statistics in China 2019–2021: A multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4( 3): 203- 213. DOI: 10.1016/j.jncc.2024.06.005.
    [4] Tan E Y, Danpanichkul P, Yong J N, et al. Liver cancer in 2021: Global burden of disease study[J]. J Hepatol, 2025, 82( 5): 851- 860. DOI: 10.1016/j.jhep.2024.10.031.
    [5] Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006.
    [6] Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.
    [7] National Health Commission of the People’s Republic of China. Guideline for diagnosis and treatment of primary liver cancer(2026 edition)[J]. J Clin Hepatol, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.
    [8] Yang Y, Yu H L, Qi L Y, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis[J]. Int J Hyperthermia, 2022, 39( 1): 455- 465. DOI: 10.1080/02656736.2022.2048095.
    [9] Ding J M, Long L, Zhang X, et al. Contrast-enhanced ultrasound LI-RADS 2017: Comparison with CT/MRI LI-RADS[J]. Eur Radiol, 2021, 31( 2): 847- 854. DOI: 10.1007/s00330-020-07159-z.
    [10] Zhou Y, Qin Z Y, Ding J M, et al. Risk stratification and distribution of hepatocellular carcinomas in CEUS and CT/MRI LI-RADS: A meta-analysis[J]. Front Oncol, 2022, 12: 873913. DOI: 10.3389/fonc.2022.873913.
    [11] Qiu S B, Ding J M, Wang Y D, et al. Dynamic contrast-enhanced ultrasonography combined with LR-M classification criteria for differentiating malignant liver nodules at high risk for hepatocellular carcinoma[J]. Ultrasound Med Biol, 2024, 50( 7): 1028- 1033. DOI: 10.1016/j.ultrasmedbio.2024.03.016.
    [12] Badiu S M, Gheorghe E C, Nicolau C, et al. Quantitative time intensity curve analysis of contrast-enhanced ultrasound(CEUS) examinations for the assessment of focal liver lesions[J]. Med Ultrason, 2024, 26( 1): 63- 71. DOI: 10.11152/mu-4108.
    [13] Ying X Q, Dong S X, Zhao Y Y, et al. Research progress on contrast-enhanced ultrasound(CEUS) assisted diagnosis and treatment in liver-related diseases[J]. Int J Med Sci, 2025, 22( 5): 1092- 1108. DOI: 10.7150/ijms.101789.
    [14] Qin Z, Zhou Y, Ding J, et al. Risk stratification for hepatocellular carcinoma of contrast-enhanced ultrasound Liver Imaging Reporting and Data System(LI-RADS) and the diagnostic performance of LR-5 and LR-M: A systematic review and meta-analysis[J]. Clin Radiol, 2022, 77( 4): e280- e286. DOI: 10.1016/j.crad.2022.01.041.
    [15] Park J H, Park M S, Lee S J, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: A multicenter diagnostic trial(SCAN)[J]. Radiology, 2019, 292( 3): 638- 646. DOI: 10.1148/radiol.2019190183.
    [16] Meloni M F, Francica G, Chiang J, et al. Use of contrast-enhanced ultrasound in ablation therapy of HCC: Planning, guiding, and assessing treatment response[J]. J Ultrasound Med, 2021, 40( 5): 879- 894. DOI: 10.1002/jum.15471.
    [17] Wang F H, Zhang Q, Yan K, et al. 3D-CEUS/MRI–CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: A multicenter prospective study of therapeutic responseevaluation[J]. Eur Radiol, 2025, 35( 1): 453- 462. DOI: 10.1007/s00330-024-10915-0.
    [18] Kim Y R, Kim E, Kim H I, et al. Updated network meta-analysis of first-line systemic treatments for advanced HCC: Consistent role of TACE[J]. Liver Cancer, 2026, 15( 1): 117- 134. DOI: 10.1159/000546697.
    [19] Zhou Hongyu, Zhou Yan, Ding Jianmin, et al. Long term outcome of combining transarterial chemoembolization and radiofrequency ablation therapy for large hepatocellular carcinoma[J/OL]. Chin J Med Ultrasound Electron Ed, 2018, 15( 9): 700- 706. DOI: 10.3877/cma.j.issn.1672-6448.2018.09.011.

    周洪雨, 周燕, 丁建民, 等. 肝动脉化疗栓塞联合射频消融治疗直径≥5 cm肝细胞癌患者10年疗效及预后分析[J/OL]. 中华医学超声杂志(电子版), 2018, 15( 9): 700- 706. DOI: 10.3877/cma.j.issn.1672-6448.2018.09.011.
    [20] Lyshchik A, Fetzer D T, Kono Y, et al. Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024[J]. Radiology, 2024, 311( 2): e232369. DOI: 10.1148/radiol.232369.
    [21] Yao J Q, Guo H L, Zhang X E, et al. Local tumor progression after hepatocellular carcinoma ablation: CEUS LI-RADS nonradiation TRA version 2024 versus a modified algorithm[J]. Ultrasound Med Biol, 2026, 52( 6): 1116- 1124. DOI: 10.1016/j.ultrasmedbio.2026.02.012.
    [22] Kuon Yeng Escalante C M, Siu Xiao T, Nagaraj R U, et al. Evaluation of the contrast-enhanced ultrasound nonradiation treatment response assessment LI-RADS v2024 using data from a multi-center transarterial chemoembolization study[J]. Acad Radiol, 2024, 31( 12): 5078- 5086. DOI: 10.1016/j.acra.2024.06.005.
    [23] Ding J M, Wang D, Zhou Y, et al. A novel mono-modality fusion imaging method based on three-dimensional contrast-enhanced ultrasound for the evaluation of ablation margins after microwave ablation of hepatocellular carcinoma[J]. J Gastrointest Oncol, 2021, 12( 1): 184- 195. DOI: 10.21037/jgo-21-46.
    [24] Zhou Y, Wang Y D, Wang F M, et al. Additional diagnostic value of fusion imaging of CEUS and first CEUS of invisible hepatic lesions ≤2 cm[J]. J Ultrasound Med, 2021, 40( 6): 1173- 1181. DOI: 10.1002/jum.15498.
    [25] Lee Y, Yoon J H, Han S, et al. Contrast-enhanced ultrasonography-CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: Improving feasibility and therapeutic outcome[J]. Cancer Imaging, 2024, 24( 1): 4. DOI: 10.1186/s40644-023-00650-y.
    [26] Zhang X D, He X Q, Zeng Q J, et al. Utility of fusion imaging for percutaneous thermal ablation of hepatocellular carcinoma in the caudate lobe[J]. J Vasc Interv Radiol, 2021, 32( 8): 1209- 1214. DOI: 10.1016/j.jvir.2021.04.028.
    [27] You Y J, Long Y L, Yan R H, et al. Improving ablation safety for hepatocellular carcinoma proximal to the hilar bile ducts by ultrasound-MR fusion imaging: A preliminary comparative study[J]. Front Oncol, 2021, 11: 570312. DOI: 10.3389/fonc.2021.570312.
    [28] Luo L P, He X Q, Li K, et al. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 5): 101581. DOI: 10.1016/j.clinre.2020.11.011.
    [29] Liu J M, Guo Y Q, Sun Y T, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma[J]. Int J Hyperthermia, 2024, 41( 1): 2316097. DOI: 10.1080/02656736.2024.2316097.
    [30] Shiina S, Tateishi R, Choi J I, et al. Asian conference on tumor ablation guidelines for hepatocellular carcinoma[J]. Liver Cancer, 2025, 14( 5): 651- 678. DOI: 10.1159/000544976.
    [31] Odisio B C, Albuquerque J, Lin Y M, et al. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation(COVER-ALL): A randomised phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2025, 10( 5): 442- 451. DOI: 10.1016/S2468-1253(25)00024-X.
    [32] Zhou H Y, Yang G H, Jing X, et al. Predictive value of ablative margin assessment after microwave ablation for local tumor progression in medium and large hepatocellular carcinoma: Computed tomography-computed tomography image fusion method versus side-by-side method[J]. J Comput Assist Tomogr, 2023, 47( 1): 31- 37. DOI: 10.1097/RCT.0000000000001395.
    [33] Ding W Z, Wu J P, Dou J P, et al. Biologically explicable multimodal model predicting local tumor progression and tumor invasiveness of hepatocellular carcinoma[J]. Hepatology, 2026. DOI: 10.1097/HEP.0000000000001678.[ Online ahead of print]
    [34] Xu E J, Li K, Long Y L, et al. Intra-procedural CT/MR-ultrasound fusion imaging helps to improve outcomes of thermal ablation for hepatocellular carcinoma: Results in 502 nodules[J]. Ultraschall Med, 2021, 42( 2): e9- e19. DOI: 10.1055/a-1021-1616.
    [35] Paolucci I, Overduin C G, Johnston E W, et al. International multisociety Delphi consensus for liver tumour thermal ablation: Margin assessment[J]. Lancet Oncol, 2026, 27( 5): e248- e258. DOI: 10.1016/S1470-2045(26)00143-9.
    [36] Laimer G, Johnston E W, Overduin C G, et al. International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards[J]. Lancet Oncol, 2026, 27( 5): e259- e270. DOI: 10.1016/S1470-2045(26)00114-2.
  • 加载中
计量
  • 文章访问数:  5
  • HTML全文浏览量:  0
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2026-06-12
  • 录用日期:  2026-07-16
  • 出版日期:  2026-07-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回